Bulletin from Extraordinary General Meeting of Diamyd Medical AB

  Bulletin from Extraordinary General Meeting of Diamyd Medical AB

Business Wire

STOCKHOLM -- January 31, 2013

Regulatory News:

At the Extraordinary General Meeting of Diamyd Medical AB (publ) held today,
none of the proposals regarding reduction of the share capital for repayment
to shareholders reached the required majority pursuant to the Companies Act.
As a consequence, the proposal regarding stock dividend lapsed.

About Diamyd Medical

Diamyd Medical was founded in 1996 and is active in the field of
pharmaceutical development. Diamyd Medical is headquartered in Stockholm,
Sweden. The Company’s development project consists of the protein GAD for the
treatment and prevention of autoimmune diabetes. A Swedish
researcher-initiated Phase II study is ongoing to evaluate whether GAD can
prevent type 1 diabetes in children who are at high risk of developing the

Diamyd Medical also has holdings in the gene therapy company Periphagen
Holdings, Inc. (USA), the vaccine company Protein Sciences Corporation (USA)
and the diagnostics company Mercodia AB (Sweden).

Diamyd shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm
(ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the
Pink OTC Markets and the Bank of New York Mellon (PAL). Further information is
available on the Company’s website: www.diamyd.com.

This information is disclosed in accordance with the Swedish Securities
Markets Act, the Swedish Financial Instruments Trading Act, or the
requirements stated in the listing agreements.

Diamyd Medical AB (publ)

Karlavägen 108, SE-115 26 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46
8 661 63 68 E-mail: info@diamyd.com. Reg. no: 556530-1420

This information was brought to you by Cision http://www.cisionwire.com


Diamyd Medical AB
Peter Zerhouni
President and CEO
Phone: +46 8 661 00 26
E-mail: press@diamyd.com
Press spacebar to pause and continue. Press esc to stop.